Misakian to Head IR at ICN Pharmaceuticals
Charting the future of public relations
Holmes Report
CEO

Misakian to Head IR at ICN Pharmaceuticals

ICN Pharmaceuticals has named Jeffrey Misakian as vice president, investor relations. He will establish the company’s investor relations program and oversee all communications with the investment community.

Paul Holmes

COSTA MESA—ICN Pharmaceuticals has named Jeffrey Misakian as vice president, investor relations. He will establish the company’s investor relations program and oversee all communications with the investment community.

Misakian most recently served as senior vice president, corporate services at Hill & Knowlton, where he provided senior counsel to corporations on investor relations and corporate communications issues. He also led Hill & Knowlton’s transactions and restructuring practice. For the past year, Misakian has worked side-by-side with ICN’s management team helping develop IR strategies for the company.

“We have been working closely with Jeff through the company’s recent changes where he provided strategic counsel to the company and served as the day-to-day investor contact for ICN. His broad background brings a strong blend of finance and investor relations skills that will be critical to ICN as we build our investor communications efforts,” said Bary Bailey, ICN’s chief financial officer.

Prior to his position with H&K, Misakian served as Vice president, investor relations at CB Richard Ellis Services, and spent several years at Golden State Bancorp/Glendale Federal Bank.

View Style:

Load 3 More
comments powered by Disqus